Ayoub Walid S, Geller Stephen A, Tran Tram, Martin Paul, Vierling John M, Poordad F Fred
Center for Liver and Kidney Diseases and Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
J Clin Gastroenterol. 2005 Jan;39(1):75-7.
Imatinib (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.
伊马替尼（格列卫，诺华制药公司，新泽西州东哈嫩）被广泛用于治疗慢性粒细胞白血病和胃肠道间质瘤。据我们所知，仅有一篇关于经组织学证实的伊马替尼诱导的肝毒性的病例报告。我们描述了另一例22岁女性肝毒性病例，包括组织病理学变化以及停用伊马替尼后的临床病程。
